forum

NATCOPHARM Share Price Discussion

Natco Pharma Ltd.
Sector: Pharmaceuticals and health care
... Read more
NATCOPHARM Share Price *
560.85 -7.8 (-1.37%)
* (quote may be delayed)

NATCOPHARM Discussion Forum

Brokerages initiate coverage on these 8 stocks in September, expect 13-52% return
The market is likely to remain in a tight range due to lack of domestic triggers as well as mixed global cues," Siddhartha Khemka, Head - Retail Research at MOFSL told Moneycontrol.
Moneycontrol
Like
reply
Reply
share
Share

Sell natcopharma below 566 cmp 576 tgt open
For sure call what's app me on 7276280387
Like
reply
Reply
share
Share

BUYYYYYYYYYYYYYYYYYYYY Natco Pharma 565/- sl 558 tr 580/-590
Like
reply
Reply
share
Share
Rupee headwinds will put pressure on equities; could retest Rs 74/$ in near term
Rupee successfully retested its multi-year breakout zone of 69 and is poised to retest its previous zone of Rs 74.5/$ and could even breach it
Moneycontrol
Like
reply
Reply
share
Share
Piramal Enterprises slips 3% after board defers NCD issue
The share touched its 52-week high Rs 3,302.55 and 52-week low Rs 1,651.80 on 31 August, 2018 and 07 August, 2019, respectively.
Moneycontrol
Like
reply
Reply
share
Share
Hold Natco Pharma; target of Rs 595: ICICI Direct
ICICI Direct recommended hold rating on Natco Pharma with a target price of Rs 595 in its research report dated August 12, 2019.
moneycontrol.com
Like
reply
Reply
share
Share
Stocks in the news: RIL, Tata Motors, ONGC, BHEL, BPCL, Sintex Plastics, Varroc Engg, Oil India
Tata Motors | Alembic | Bosch | National Aluminium Company | Unichem Laboratories | ONGC | BHEL | BPCL and Sintex Plastics are among stocks, which are in news today.
moneycontrol.com
Like
reply
Reply
share
Share
Natco Pharma gets EIR from USFDA for Kothur facility
The receipt of EIR from the United States Food and Drug Administration (USFDA) indicates the successful closure of inspection of the company’s drug formulations facility in Kothur, Natco Pharma said in a BSE filing.
moneycontrol.com
Like
reply
Reply
share
Share
Buy Piramal Enterprises; target of Rs 2400: Motilal Oswal
Motilal Oswal is bullish on Piramal Enterprises has recommended buy rating on the stock with a target price of Rs 2400 in its research report dated July 30, 2019.
moneycontrol.com
Like
reply
Reply
share
Share
Pfizer’s Upjohn-Mylan merger may have little impact on India operations
As part of the Upjohn-Mylan deal, the Indian unit of US drug major Pfizer announced on July 30 that it will be transferring six brands to the combined entity.
moneycontrol.com
Like
reply
Reply
share
Share
Piramal Enterprises Q1 net up 21% at Rs 461 cr
Net sales rose 21 per cent to Rs 3,506 crore in the latest quarter as against Rs 2,902 crore in June quarter 2018-19, Piramal Enterprises said in a statement.
moneycontrol.com
Like
reply
Reply
share
Share
Piramal Enter Consolidated June 2019 Net Sales at Rs 3,506.25 crore, up 20.8% Y-o-Y
www.moneycontrol.com
Like
reply
Reply
share
Share
Piramal Enter Standalone June 2019 Net Sales at Rs 871.98 crore, up 0.98% Y-o-Y
moneycontrol.com
Like
reply
Reply
share
Share
Piramal Capital eyes buyouts worth $600m in NBFC space; targets DHFL’s porfolio: Report
In June, Piramal Enterprises sold its entire stake (nearly 10 percent) in Shriram Transport Finance to institutional investors for Rs 2,300 crore
moneycontrol.com
Like
reply
Reply
share
Share
Like
reply
Reply
share
Share
Like
reply
Reply
share
Share
Like
reply
Reply
share
Share
Like
reply
Reply
share
Share
Like
reply
Reply
share
Share
Like
reply
Reply
share
Share
Like
reply
Reply
share
Share
Like
reply
Reply
share
Share
Like
reply
Reply
share
Share
Like
reply
Reply
share
Share
Like
reply
Reply
share
Share
Like
reply
Reply
share
Share
Like
reply
Reply
share
Share
Like
reply
Reply
share
Share
Like
reply
Reply
share
Share
Like
reply
Reply
share
Share
  • NATCOPHARM - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization13,915.91
    Enterprise Value13,916.81
    Price to Earnings19.94
    Price to Book Value4.45
    Return on Capital Employed0.27
    Return on Equity0.22
    Face Value2
    Dividend Yield0.01
  • NATCOPHARM Share Price - Technicals

    keyboard_arrow_down
    NATCOPHARM - 52 Week High₹830.95
    NATCOPHARM - 52 Week Low₹480
  • NATCOPHARM - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    13-Aug-19Nirmal BangBuy654
    9-Aug-19AnandRathiBuy763
    31-May-19Geojit Financial ServicesSell487
    29-May-19ICICIdirect.comHold595
    29-May-19Nirmal BangBuy654
    View all NATCOPHARM - Share Targets - Broker Reports
  • NATCOPHARM Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Sep 16565574.45557.3563.1
    Sep 13560570.25553.05568.65
    Sep 12576.2583.6558.1562.1
    Sep 11586591.6574.25578.95
    Sep 9566587.4565583.45
  • NATCOPHARM Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹551.92
    30 Day Moving Average₹547.61
    50 Day Moving Average₹536.83
    100 Day Moving Average₹534.8
    200 Day Moving Average₹588.79
  • NATCOPHARM - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue2,0912,002.80.04
    Operating Profit9286920.34
    Profit Before Tax888634.10.4
    Net Income698494.80.41
  • NATCOPHARM - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Shareholder's Funds3,1261,699.70.84
    Total Liabilities612648.4-0.06
    Total Assets3,7372,348.10.59
  • NATCOPHARM - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity476329.80.44
    Cash from Investing Activity-1,131-290.62.89
    Cash from Financing Activity652-170.2-4.83
    Net Cash Flow-3-131-0.98
  • NATCOPHARM - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.190.21
    Return on Equity0.220.29
    Return on Capital Employed0.270.34
  • NATCOPHARM - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue1.92
    3 Year CAGR Growth in Operating Profit3.35
    3 Year CAGR Growth in EBIDTA3.26
    3 Year CAGR Growth in Net Income3.56
    3 Yr CAGR Growth - Diluted EPS-0.18
  • NATCOPHARM - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue2.75
    5 Year CAGR Growth in Operating Profit5.39
    5 Year CAGR Growth in EBIDTA5.15
    5 Year CAGR Growth in Net Income7.93
    3 Yr CAGR Growth - Diluted EPS0.52
  • NATCOPHARM Share Price - Recent News

    keyboard_arrow_down
    NewsBot
    Sep 12 7:33 PM
    Brokerages initiate coverage on these 8 stocks in September, expect 13-52% return
    Moneycontrol
    NewsBot
    Sep 1 2:23 PM
    Rupee headwinds will put pressure on equities; could retest Rs 74/$ in near term
    Moneycontrol
    NewsBot
    Aug 29 3:38 PM
    Piramal Enterprises slips 3% after board defers NCD issue
    Moneycontrol
    NewsBot
    Aug 13 6:43 PM
    Hold Natco Pharma; target of Rs 595: ICICI Direct
    moneycontrol.com
    NewsBot
    Aug 13 1:23 PM
    Stocks in the news: RIL, Tata Motors, ONGC, BHEL, BPCL, Sintex Plastics, Varroc Engg, Oil India
    moneycontrol.com
    NewsBot
    Aug 5 7:18 PM
    Natco Pharma gets EIR from USFDA for Kothur facility
    moneycontrol.com
    NewsBot
    Jul 31 9:53 PM
    Buy Piramal Enterprises; target of Rs 2400: Motilal Oswal
    moneycontrol.com
    NewsBot
    Jul 31 2:58 AM
    Pfizer’s Upjohn-Mylan merger may have little impact on India operations
    moneycontrol.com
    NewsBot
    Jul 30 9:43 PM
    Piramal Enterprises Q1 net up 21% at Rs 461 cr
    moneycontrol.com
    NewsBot
    Jul 30 7:28 PM
    Piramal Enter Consolidated June 2019 Net Sales at Rs 3,506.25 crore, up 20.8% Y-o-Y
    www.moneycontrol.com
  • NATCOPHARM - Related Communities

    keyboard_arrow_down
    Wanbury Ltd. Sector: Pharmaceuticals ...
    Piramal Phytocare Ltd. Sector: Pharma...
    Parabolic Drugs Ltd. Sector: Pharmace...
    Orchid Pharma Ltd. Sector: Pharmaceut...
    Biofil Chemicals & Pharmaceuticals Lt...
    Wockhardt Ltd. Sector: Pharmaceutical...
    Vivimed Labs Ltd. Sector: Pharmaceuti...
    Venus Remedies Ltd. Sector: Pharmaceu...
    Unichem Laboratories Ltd. Sector: Pha...
    TTK Healthcare Ltd. Sector: Pharmaceu...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.